Immunotherapy of metastasis

Surgical Oncology Clinics of North America

Volumn 10, Issue 2, 2001, Pages 433-447

  Dallal, R M ^a   Lotze, M T ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CANCER VACCINE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PEPTIDE; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; GENE TRANSFER; HUMAN; IMMUNOBIOLOGY; LYMPHOCYTE FUNCTION; METASTASIS; NONHUMAN; REVIEW; SOLID TUMOR; T LYMPHOCYTE;

EID: 0034996040     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1055-3207(18)30074-7     Document Type: Review

References (63)

1. Abdel-Wahab Z. Weltz C. Hester D. A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: Monitoring the humoral immune response Cancer 80 1997 401 412
2. Albert M.L. Sauter B. Bhardwaj Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs Nature 392 1998 86 89
3. Alters S.E. Gadea J.R. Philip R. Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells Adv Exp Med Biol 417 1997 519 524
4. Amoscato A.A. Prenovitz D.A. Lotze M.T. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells J Immunol 161 1998 4023 4032
5. Ashley D.M. Faiola B. Nair S. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors J Exp Med 186 1997 1177 1182
6. Atkins M.B. Lotze M. Wiernick P. High-dose IL-2 therapy alone results in long-term durable complete responses in patients with metastatic melanoma Proceedings of the American Society of Clinical Oncology 16 1997 494a
7. Belli F. Mascheroni L. Gallino G. Active immunization of metastatic melanoma patients with IL-2 or IL-4 gene transfected, allogenic melanoma cells Adv Exp Med Bio 451 1998 543 545
8. Bello-Fernandez C. Matyash M. Strobl H. Efficient retrovirus-mediated gene transfer of dendritic cells generated from CD34+ cord blood cells under serum-free conditions Human Gene Therapy 8 1997 1651 1658
9. Boczkowski D. Nair S.K. Nam J. Induction of tumor immunity and cytotoxic T lymphocytes responses using dendritic cells transfected with messenger RNA amplified from tumor cells Cancer Res 60 2000 1028 1034
10. Chatterjee S.K. Qin H. Manna S. Recombinant vaccinia vims expressing cytokine GM-CSF as tumor vaccine Anticancer Res 19 1999 2869 2873
11. Condon C. Watkins S.C. Celluzzi C.M. DNA-based immunization by in vivo transfection of dendritic cells Nature Medicine 2 1996 1122 1128
12. Conry R.M. Allen K.O. Lee S. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine Clin Cancer Res 6 2000 34 41
13. Davis I.D. Lotze M.T. Cytokine gene therapy Thomson A. The Cytokine Handbook ed 3 1997 Academic Press London 823 854
14. Dranoff G. Jaffee E. Lazenby A. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 90 1993 3539 3543
15. Ellem K.A. O’Rourke M.G. Johnson G.R. A case report: Immune responses and clinical course of the first human use of granulocyte / macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy Cancer Immunol Immunother 44 1997 10 20
16. Gervois N. Guilloux Y. Diez E. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions J Exp Med 183 1996 2403 2407
17. Gure A.O. Tureci O. Sahin U. SSX: A multigene family with several members transcribed in normal testis and human cancer Int J Cancer 14 1997 173 192
18. Harris I.E. Ryan L. Hoover H.C. Jr. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283 J Clin Oncol 18 2000 148 157
19. Hart I. Colaco C. Immunotherapy: Fusion induces tumor rejection Nature 388 1997 626 627
20. Houghton A.N. Mintzer D. Cordon-Cardo C. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma Proc Natl Acad Sci USA 82 1985 1242 1246
21. Houghton A.N. Scheinberg D.A. Monoclonal antibody therapies—A “constant” threat to cancer Nat Med 6 2000 373 374
22. Hsu F.J. Benike C. Fagnoni F. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells Nat Med 2 1996 52 58
23. Hsueh E.C. Famatiga E. Gupta R.K. Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): Correlation with survival Ann Surg Oncol 5 1998 595 602
24. Jager E. Ringhoffer M. Dienes H.P. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo Int J Cancer 67 1996 54 62
25. Kim C.J. Prevette T. Cormier J. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro J Immunother 20 1997 276 286
26. Kobayashi Y. Higashi T. Nouso K. Expression of MAGE, GAGE and BAGE genes in human liver diseases: Utility as molecular markers for hepatocellular carcinoma J Hepatol 32 2000 612 617
27. Kugler A. Stuhler G. Walden P. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids Nat Med 6 2000 332 336
28. Lotze M.T. Roberts K. Custer M.C. Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: A possible approach to the immunotherapy of human tumors J Surg Res 42 1987 580 589
29. Lotze M.T. Shurin M. Esche C. Interleukin-2: Developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity Cancer J Sci Am 6 2000 S61 S66 Suppl 1
30. + cytotoxic T-lymphocytes J Clin Invest 98 1996 1633 1641
31. Manickan E. Kanangat S. Rouse R.J.D. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells J Leukoc Biol 61 1997 125
32. McCaffery M. Yao T.J. Williams L. Immunization of melanoma patients with BEC2 antiidiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant Clin Cancer Res 2 1996 679 686
33. Mittelman A. Chen Z.J. Kageshita T. Active specific immunotherapy in patients with melanoma: A clinical trial with mouse anti-idiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies J Clin Invest 86 1990 2136 2144
34. Mittelman A. Wang X. Matsumoto K. Antianti-idiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse anti-idiotypic monoclonal antibody MK2-23 Hybidoma 14 1995 175 181
35. Moroi Y. Mayhew M. Trcka J. An induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70 Proc Natl Acad Sci USA 97 2000 3485 3490
36. Murphy G. Tjoa B. Ragde H. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A20201-specific peptides from prostate-specific membrane antigen Prostate 29 1996 371 380
37. Nasi M.L. Meyers M. Livingston P.O. Antimelanoma effects of R24, a monoclonal antibody against GD3 ganglioside Melanoma Res 1997 S155 S162 7 Suppl 2
38. Nestle F.O. Alijagic S. Gilliet M. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat Med 4 1998 328 332
39. Nishioka Y. Shurin M. Robbins P.D. Effective tumor immunotherapy using bone marrow-derived dendritic cells (DC)’s genetically engineered to express interleukin 12 J Immunother 20 1997 419
40. Palmer K. Moore J. Everard M. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma Hum Gene Ther 10 1999 1261 1268
41. Parkhurst M.R. Salgaller M.L. Southwood S. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gplOO modified at HLA-A* 0201-binding residues J Immunol 157 1996 2539 2548
42. Pellat-Deceunynck C. Mellerin M.P. Labarriere N. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells Eur J Immunol 30 2000 803 809
43. Peoples G.E. Anderson B.W. Lee T.V. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers Clin Cancer Res 5 1999 4214 4223
44. Rosenberg S.A. Yang J.C. Schwartzentruber D.J. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 1998 321 327
45. Ruppert J. Sidney J. Celis E. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules Cell 74 1993 929 937
46. Salgaller M. Lodge P. Use of cellular and cytokine adjuvants in the immunotherapy of cancer J Surg Oncol 68 1998 122 138
47. Salgaller M.L. Thurnher M. Bartsch G. Report from the International Union Against Cancer Tumor Biology Committee Cancer 86 1999 2674 2683
48. Sallusto F. Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor a J Exp Med 179 1994 1109 1118
49. Sauter B. Albert M.L. Francisco L. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells J Exp Med 191 2000 423 434
50. Si Z. Hersey P. Coates A.S. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF Melanoma Res 6 1996 247 255
51. Simons J.W. Jaffee E.M. Weber C.E. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer Cancer Res 57 1997 1537 1546
52. Simons J.W. Mikhak B. Chang J.F. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer Cancer Res 59 1999 5160 5168
53. Tjandrawan T. Maeurer M.J. Castelli C. Autologous dendritic cells pulsed with MART-1, gp1OO, or tyrosinase peptides elicit antimelanoma CTL from both normal donor and cancer patient peripheral blood lymphocytes in vitro J Immunother 21 1998 149 157
54. Tjoa B.A. Simmons S.J. Bowes V.A. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells Prostate 36 1998 39 44
55. Traversari C.P. Van der Bruggen I.F. Leuscher C. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E J Exp Med 176 1992 1453
56. Trefzer U. Weingart G. Chen Y. Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma Int J Cancer 85 2000 618 626
57. Tiiting T. Baar J. Gambotto A. Interferon-a gene therapy for cancer: Retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are equally effective strategies for gene delivery in murine tumor models Gene Ther 4 1997 1053 1060
58. Tuting T. Wilson C.C. Martin D.M. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T-cell responses in vitro: Enhancement by cotransfection of genes encoding the Thl-biasing cytokines IL-12 and IFN-a J Immunol 160 1998 1139 1147
59. Valmori D. Fonteneau J.F. Lizana C.M. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues J Immunol 160 1998 1750 1758
60. Wan Y. Bramson J. Carter R. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination Hum Gene Ther 8 1997 1355 1363
61. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules Annu Rev Immunol 15 1997 821 850
62. Weiner L.M. Monoclonal antibody therapy of cancer Semin Oncol 5 1999 43 51 Suppl 14
63. Yao T.J. Meyers M. Livingston P.O. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies Clin Cancer Res 5 1999 77 81